In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Fabiola Escalante-AraizaImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.ORCID 0000-0003-0508-4023 Angélica Martínez-HernándezImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.
Humberto García-OrtizImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.ORCID 0000-0002-0453-980X Eira Huerta-ÁvilaImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.ORCID 0000-0001-7984-588X José Rafael Villafan-BernalImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.
Cecilia Contreras-CubasImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.ORCID 0000-0002-7994-3831 Federico Centeno-CruzImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.ORCID 0000-0002-3512-4519 Gemm Family Study
Edna J Nava-GonzálezFacultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
José Damián Carrillo-RuizFaculty of Psychology, Universidad Anáhuac Norte, Mexico City 52786, Mexico.
Ernesto Rodriguez-AyalaFaculty of Health Sciences, Universidad Anáhuac Norte, Mexico City 52786, Mexico.
Raúl A BastarracheaPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.ORCID 0000-0002-4034-3062 Francisco Barajas-OlmosImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.ORCID 0000-0001-5064-6203 Lorena OrozcoImmunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City 14610, Mexico.
Funding
Secretaría de Ciencia, Humanidades, Tecnología e Innovación 2016-01-3251
6 · The paper itselfAbstract
Cardiometabolic phenotypes such as obesity and impaired insulin action are key determinants of type 2 diabetes (T2D). Growing evidence highlights the postprandial state as a critical window in metabolic regulation, where epigenetic mechanisms, particularly DNA methylation in insulin-sensitive tissues, may play pivotal roles. However, their dynamics across prandial states in subcutaneous adipose tissue (SAT) remain unclear. We analyzed genome-wide DNA methylation in paired fasting and postprandial SAT biopsies from 29 asymptomatic, drug-naïve individuals classified as controls (
Indexed as
Adipose TissueDiabetes Mellitus, Type 2DNA MethylationFastingPostprandial PeriodPrediabetic StateAdultAgedCpG IslandsEpigenesis, GeneticFemaleHumansInsulin ResistanceMaleMiddle Ageddifferential DNA methylationepigenetic biomarkersmixed meal challengeobesitypostprandial stateprediabetessubcutaneous adipose tissuetype 2 diabetes
Identifiers
PMID41373473
PMCPMC12692098
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390